MedTrace Logo

Pembrolizumab in Neoplasms or Lymphomas

NCT03316573 · Status: SUSPENDED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2026-02-10

Study results available
· View outcomes & findings →

Summary

This research study is studying a drug called pembrolizumab as a possible treatment for aggressive lymphoma or a histiocyte or dendritic cell neoplasm.

The drug involved in this study is:

-Pembrolizumab

Conditions

  • Lymphoma
  • Histiocytic Sarcoma
  • Follicular Dendritic Cell Sarcoma
  • Interdigitating Dendritic Cell Sarcoma

Interventions

DRUG

Pembrolizumab

The study drug is an antibody that targets a molecule called PD-1. Blocking PD-1 allow the immune system to attack the cancer more effectively.

Sponsors & Collaborators

Principal Investigators

  • Eric Jacobsen, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-07
Primary Completion
2022-08-18
Completion
2026-03-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03316573 on ClinicalTrials.gov